

Josep Dalmau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/409806/publications.pdf>

Version: 2024-02-01

421
papers

53,097
citations

1301

109
h-index

1461

220
g-index

441
all docs

441
docs citations

441
times ranked

14602
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-NMDA Receptor Encephalitis and Other Autoimmune and Paraneoplastic Movement Disorders. <i>Current Clinical Neurology</i> , 2022, , 271-291.	0.2	0
2	Characteristics of clinical relapses and patient-oriented long-term outcomes of patients with anti-N-methyl-d-aspartate receptor encephalitis. <i>Journal of Neurology</i> , 2022, 269, 2486-2492.	3.6	6
3	Antibody-mediated neuropsychiatric disorders. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 37-40.	2.9	6
4	Autoimmune Cerebellar Ataxias. , 2022, , 342-367.		0
5	Antibodies to Neural Cell Surface Antigens. , 2022, , 135-166.		1
6	Anti-NMDAR Encephalitis. , 2022, , 210-254.		0
7	Autoimmune and Inflammatory Encephalopathies as Complications of Cancer. , 2022, , 430-459.		0
8	Anti-IgLON5 Disease. , 2022, , 411-429.		0
9	Autoimmune Brainstem Encephalitis. , 2022, , 368-390.		0
10	Pathogenesis and Disease Mechanisms in Neuronal Antibody-Mediated Encephalitis. , 2022, , 42-106.		1
11	Deconstructing Hashimoto Encephalopathy. , 2022, , 460-475.		0
12	CNS Syndromes at the Frontier of Autoimmune Encephalitis. , 2022, , 476-502.		0
13	Importance, Definitions, History, Classification, and Frequency of the Autoimmune Encephalitides. , 2022, , 1-18.		1
14	Acute Disseminated Encephalomyelitis and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. , 2022, , 290-314.		0
15	Autoimmune Dementia: A Useful Term?. , 2022, , 611-629.		0
16	Seizures and Antibodies Against Surface Antigens. , 2022, , 255-289.		0
17	Autoimmune Psychosis. , 2022, , 503-526.		1
18	Frequently Asked Questions on Autoimmune Encephalitis and Related Disorders. , 2022, , 630-655.		1

#	ARTICLE	IF	CITATIONS
19	Abnormal Movements in Neurological Autoimmune Disorders. , 2022, , 545-562.		0
20	Immunity, Inflammation, and Epilepsy. , 2022, , 588-610.		0
21	Neuromyelitis Optica Spectrum Disorders and Glial Fibrillary Acidic Protein Autoimmunity. , 2022, , 315-341.		0
22	Sleep and Autoimmunity. , 2022, , 563-587.		0
23	Limbic Encephalitis. , 2022, , 167-190.		0
24	Autoimmunity Against Proteins Associated with Voltage-Gated Potassium Channels. , 2022, , 191-209.		0
25	Psychiatric Manifestations of Autoimmune Encephalitis. , 2022, , 527-544.		1
26	Antibodies to Intracellular Antigens in CNS Disorders. , 2022, , 107-134.		0
27	Autoimmunity Against the Inhibitory Synapsis. , 2022, , 391-410.		0
28	General Approach to Diagnosis. , 2022, , 19-41.		0
29	Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis. Neurology, 2022, 98, .	1.1	25
30	Human CASPR2 Antibodies Reversibly Alter Memory and the CASPR2 Protein Complex. Annals of Neurology, 2022, 91, 801-813.	5.3	17
31	Human Metabotropic Glutamate Receptor 5 Antibodies Alter Receptor Levels and Behavior in Mice. Annals of Neurology, 2022, 92, 81-86.	5.3	9
32	Allosteric Modulation of NMDARs Reverses Patients' Autoantibody Effects in Mice. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	10
33	<scp>ZSCAN1</scp> Autoantibodies Are Associated with Pediatric Paraneoplastic <scp>ROHHAD</scp>. Annals of Neurology, 2022, 92, 279-291.	5.3	17
34	Author Response: Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis. Neurology, 2022, 98, 906-906.	1.1	1
35	Seizure-related 6 homolog like 2 autoimmunity. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	36
36	Placental transfer of NMDAR antibodies causes reversible alterations in mice. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	17

#	ARTICLE	IF	CITATIONS
37	Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis. <i>Neurology</i> , 2021, 97, e61-e75.	1.1	54
38	Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	313
39	Encephalitis with Autoantibodies against the Glutamate Kainate Receptors <scp>GluK2</scp>. <i>Annals of Neurology</i> , 2021, 90, 101-117.	5.3	26
40	â€œAntibody of Unknown Significanceâ€•(AUS): The Issue of Interpreting Antibody Test Results. <i>Movement Disorders</i> , 2021, 36, 1543-1547.	3.9	11
41	Limitations of a Commercial Assay as Diagnostic Test of Autoimmune Encephalitis. <i>Frontiers in Immunology</i> , 2021, 12, 691536.	4.8	46
42	International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	70
43	Thymoma and Autoimmune Encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	28
44	Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease. <i>Neurology</i> , 2021, 97, .	1.1	50
45	Autoimmune encephalitis or autoimmune psychosis?. <i>European Neuropsychopharmacology</i> , 2021, 50, 112-114.	0.7	9
46	Blocking Placental Class G Immunoglobulin Transfer Prevents NMDA Receptor Antibody Effects in Newborn Mice. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, e1061.	6.0	2
47	Use and Safety of Immunotherapeutic Management of <i>N</i>-Methyl-<scp>d</scp>-Aspartate Receptor Antibody Encephalitis. <i>JAMA Neurology</i> , 2021, 78, 1333.	9.0	91
48	Neuropathological Variability within a Spectrum of <scp>NMDAR</scp>-â€œEncephalitis. <i>Annals of Neurology</i> , 2021, 90, 725-737.	5.3	35
49	Absence of GluD2 Antibodies in Patients With Opsoclonus-Myoclonus Syndrome. <i>Neurology</i> , 2021, 96, e1082-e1087.	1.1	9
50	Reply to: Comparing <scp>VUS</scp> and <scp>AUS</scp>: Parallels and Differences in Neurogenetics and Neuroimmunology. <i>Movement Disorders</i> , 2021, 36, 2454-2456.	3.9	0
51	N2 year in review. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, e925.	6.0	3
52	Author Response: Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis. <i>Neurology</i> , 2021, 97, 1010-1010.	1.1	1
53	Pregnancy, Nâ€œMethylâ€œAspartate Receptor Antibodies, and Neuropsychiatric Diseases. <i>Annals of Neurology</i> , 2020, 87, 324-325.	5.3	1
54	Hashimoto encephalopathy in the 21st century. <i>Neurology</i> , 2020, 94, e217-e224.	1.1	92

#	ARTICLE	IF	CITATIONS
55	Spatial Suppression and Sensitivity for Motion in Schizophrenia. Schizophrenia Bulletin Open, 2020, 1, .	1.7	9
56	Sleep disorders in autoimmune encephalitis. Lancet Neurology, The, 2020, 19, 1010-1022.	10.2	64
57	“Time to recharge” Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	0
58	Effects of <scp>IgLON5</scp> Antibodies on Neuronal Cytoskeleton: A Link between Autoimmunity and Neurodegeneration. Annals of Neurology, 2020, 88, 1023-1027.	5.3	61
59	A probable case of anti-NMDAR encephalitis from 1830. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	1
60	Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis. Neurology, 2020, 95, e3012-e3025.	1.1	60
61	Reduced serial dependence suggests deficits in synaptic potentiation in anti-NMDAR encephalitis and schizophrenia. Nature Communications, 2020, 11, 4250.	12.8	38
62	Allosteric modulation of NMDA receptors prevents the antibody effects of patients with anti-NMDAR encephalitis. Brain, 2020, 143, 2709-2720.	7.6	36
63	N2 in the time of COVID-19. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e858.	6.0	1
64	Clinical significance of Kelch-like protein 11 antibodies. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	54
65	Telemedicine assessment of long-term cognitive and functional status in anti-leucine-rich, glioma-inactivated 1 encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	29
66	GAD antibodies in neurological disorders “ insights and challenges. Nature Reviews Neurology, 2020, 16, 353-365.	10.1	134
67	Interplay between persistent activity and activity-silent dynamics in the prefrontal cortex underlies serial biases in working memory. Nature Neuroscience, 2020, 23, 1016-1024.	14.8	154
68	How DIRS is refining concepts. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e677.	6.0	0
69	Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies. Neurology, 2020, 94, e2302-e2310.	1.1	94
70	Sleep disorders in anti-NMDAR encephalitis. Neurology, 2020, 95, e671-e684.	1.1	47
71	<scp>NMDAR</scp> Antibodies Alter Dopamine Receptors and Cause Psychotic Behavior in Mice. Annals of Neurology, 2020, 88, 603-613.	5.3	31
72	Pregnancy outcomes in anti-NMDA receptor encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	30

#	ARTICLE	IF	CITATIONS
73	Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. <i>Lancet Neurology</i> , The, 2020, 19, 234-246.	10.2	207
74	N-Methyl-D-Aspartate Receptor Antibodies in Autoimmune Encephalopathy Alter Oligodendrocyte Function. <i>Annals of Neurology</i> , 2020, 87, 670-676.	5.3	28
75	Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	178
76	Paraneoplastic Neurologic Syndromes. , 2020, , 676-687.e5.		1
77	Letter by Dalmau Regarding Article, "Serum Anti-NMDA (N-Methyl-D-Aspartate)-Receptor Antibodies and Long-Term Clinical Outcome After Stroke (PROSCIS-B)" <i>Stroke</i> , 2020, 51, e28.	2.0	1
78	N2 year in review. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e644.	6.0	1
79	Clinical features of seronegative, but CSF antibody-positive, anti-NMDA receptor encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e659.	6.0	30
80	Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	39
81	A call for a global COVID-19 Neuro Research Coalition. <i>Lancet Neurology</i> , The, 2020, 19, 482-484.	10.2	22
82	An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. <i>Lancet Neurology</i> , The, 2019, 18, 1045-1057.	10.2	497
83	Chronic inflammatory demyelinating polyneuropathy associated with contactin-1 antibodies in a child. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	6.0	13
84	Considerations of psychotic symptomatology in anti-NMDA encephalitis: Similarity to cycloid psychosis. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 2456-2461.	0.5	13
85	Characterization of the sleep disorder of anti-IgLON5 disease. <i>Sleep</i> , 2019, 42, .	1.1	52
86	Identification of adenylate kinase 5 antibodies during routine diagnostics in a tissue-based assay: Three new cases and a review of the literature. <i>Journal of Neuroimmunology</i> , 2019, 334, 576975.	2.3	17
87	Caveats and Pitfalls of SOX1 Autoantibody Testing With a Commercial Line Blot Assay in Paraneoplastic Neurological Investigations. <i>Frontiers in Immunology</i> , 2019, 10, 769.	4.8	26
88	Recognizing autoimmune encephalitis as a cause of seizures. <i>Neurology</i> , 2019, 92, 877-878.	1.1	8
89	N2 year in review and message from the editor to our reviewers. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e525.	6.0	1
90	Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 535-548.	27.6	186

#	ARTICLE	IF	CITATIONS
91	Seizures and movement disorders: phenomenology, diagnostic challenges and therapeutic approaches. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 920-928.	1.9	22
92	Horizontal saccadic palsy as a prominent symptom of anti-NMDAR encephalitis. Neurology: Clinical Practice, 2019, 11, 10.1212/CPJ.0000000000000750.	1.6	0
93	Late-onset neuromyelitis optica spectrum disorder. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	6.0	44
94	Toll-like receptor 3 deficiency in autoimmune encephalitis post-herpes simplex encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e611.	6.0	18
95	HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	6.0	55
96	A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis. Neurology, 2019, 92, e244-e252.	1.1	183
97	Mouse model of anti-NMDA receptor post-herpes simplex encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e529.	6.0	44
98	Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease. Multiple Sclerosis and Related Disorders, 2019, 28, 230-234.	2.0	18
99	Autoimmune seizures and epilepsy. Journal of Clinical Investigation, 2019, 129, 926-940.	8.2	152
100	Antibody-Mediated Encephalitis. New England Journal of Medicine, 2018, 378, 840-851.	27.0	812
101	Looks can be deceiving. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e461.	6.0	2
102	Encephalitis with mGluR5 antibodies. Neurology, 2018, 90, e1964-e1972.	1.1	139
103	Clinical and pathogenic significance of IgG, IgA, and IgM antibodies against the NMDA receptor. Neurology, 2018, 90, e1386-e1394.	1.1	120
104	Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies. Multiple Sclerosis Journal, 2018, 24, 1753-1759.	3.0	71
105	Paraneoplastic Syndromes of the Nervous System as Complications of Cancer. , 2018, , 221-238.		1
106	Mechanisms of Caspr2 antibodies in autoimmune encephalitis and neuromyotonia. Annals of Neurology, 2018, 83, 40-51.	5.3	71
107	Encefalitis por anticuerpos contra el receptor de NMDA. Medicina Clínica, 2018, 151, 71-79.	0.6	39
108	Importance of clinical observations. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e442.	6.0	0

#	ARTICLE	IF	CITATIONS
109	Message from the Editor to our Reviewers. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e426.	6.0	0
110	LG11 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity and memory. <i>Brain</i> , 2018, 141, 3144-3159.	7.6	112
111	Acute disseminated encephalomyelitis: A rare autoimmune complication of herpes simplex encephalitis in the adult. <i>Clinical Neurology and Neurosurgery</i> , 2018, 175, 47-49.	1.4	3
112	NMDA Receptor Autoantibodies in Autoimmune Encephalitis Cause a Subunit-Specific Nanoscale Redistribution of NMDA Receptors. <i>Cell Reports</i> , 2018, 23, 3759-3768.	6.4	61
113	Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. <i>Lancet Neurology</i> , The, 2018, 17, 760-772.	10.2	422
114	Human Autoantibodies against the AMPA Receptor Subunit GluA2 Induce Receptor Reorganization and Memory Dysfunction. <i>Neuron</i> , 2018, 100, 91-105.e9.	8.1	90
115	Encephalitis associated with antibodies against the NMDA receptor. <i>Medicina Clínica (English Edition)</i> , 2018, 151, 71-79.	0.2	11
116	Paraneoplastic Neurologic Syndromes. <i>Neurologic Clinics</i> , 2018, 36, 675-685.	1.8	41
117	Neuroimmune disorders of the central nervous system in children in the molecular era. <i>Nature Reviews Neurology</i> , 2018, 14, 433-445.	10.1	41
118	Do we need to measure specific antibodies in patients with limbic encephalitis?. <i>Neurology</i> , 2017, 88, 508-509.	1.1	9
119	Author response: The clinical spectrum of Caspr2 antibody-associated disease. <i>Neurology</i> , 2017, 88, 333-334.	1.1	1
120	Investigations in GABA _A receptor antibody-associated encephalitis. <i>Neurology</i> , 2017, 88, 1012-1020.	1.1	257
121	Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis. <i>Neurology</i> , 2017, 88, 1235-1242.	1.1	28
122	DPPX antibody-associated encephalitis. <i>Neurology</i> , 2017, 88, 1340-1348.	1.1	170
123	The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis. <i>Nature Reviews Neurology</i> , 2017, 13, 290-301.	10.1	186
124	Precision in neuroimmunology. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e345.	6.0	5
125	Clinical manifestations of the anti-IgLON5 disease. <i>Neurology</i> , 2017, 88, 1736-1743.	1.1	300
126	Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis. <i>Current Opinion in Neurology</i> , 2017, 30, 345-353.	3.6	138

#	ARTICLE	IF	CITATIONS
127	Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. <i>Physiological Reviews</i> , 2017, 97, 839-887.	28.8	428
128	Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies. <i>Epilepsy Research</i> , 2017, 129, 101-105.	1.6	67
129	Antibody-associated CNS syndromes without signs of inflammation in the elderly. <i>Neurology</i> , 2017, 89, 1471-1475.	1.1	97
130	Dynamic disorganization of synaptic NMDA receptors triggered by autoantibodies from psychotic patients. <i>Nature Communications</i> , 2017, 8, 1791.	12.8	103
131	The case for autoimmune neurology. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e373.	6.0	5
132	Hodgkin's lymphoma associated with paraneoplastic cerebellar degeneration in children: a case report and review of the literature. <i>Child's Nervous System</i> , 2017, 33, 509-512.	1.1	12
133	In vitro effects of a human monoclonal antibody against the N-methyl-D-aspartate receptor. <i>Brain</i> , 2017, 140, e9-e9.	7.6	1
134	<scp>NMDAR</scp> encephalitis: passive transfer from man to mouse by a recombinant antibody. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 768-783.	3.7	101
135	Neuropathological criteria of anti-IgLON5-related tauopathy. <i>Acta Neuropathologica</i> , 2016, 132, 531-543.	7.7	173
136	A box of chocolates. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e234.	6.0	0
137	NMDA receptor encephalitis and other antibody-mediated disorders of the synapse. <i>Neurology</i> , 2016, 87, 2471-2482.	1.1	178
138	Anti-NMDA Receptor Encephalitis, Autoimmunity, and Psychosis. <i>Focus (American Psychiatric)</i> Tj ETQq0 0 0 rgBT /Overlock 1Q Tf 50 302 0.8	0.8	5
139	Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. <i>Journal of Neuroinflammation</i> , 2016, 13, 226.	7.2	94
140	Clinical and Immunologic Investigations in Patients With Stiff-Person Spectrum Disorder. <i>JAMA Neurology</i> , 2016, 73, 714.	9.0	135
141	Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. <i>Journal of Neurology</i> , 2016, 263, 1349-1360.	3.6	112
142	NMDA Receptor Internalization by Autoantibodies: A Reversible Mechanism Underlying Psychosis?. <i>Trends in Neurosciences</i> , 2016, 39, 300-310.	8.6	73
143	Association of Progressive Cerebellar Atrophy With Long-term Outcome in Patients With Anti-N-Methyl-Aspartate Receptor Encephalitis. <i>JAMA Neurology</i> , 2016, 73, 706.	9.0	74
144	Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodiesâ€”Reply. <i>JAMA Neurology</i> , 2016, 73, 891.	9.0	2

#	ARTICLE	IF	CITATIONS
145	Human neuroligin-3 antibodies associate with encephalitis and alter synapse development. <i>Neurology</i> , 2016, 86, 2235-2242.	1.1	116
146	Cerebellar ataxia and autoantibodies restricted to glutamic acid decarboxylase 67 (GAD67). <i>Journal of Neuroimmunology</i> , 2016, 300, 15-17.	2.3	14
147	Anti-LGI1-associated cognitive impairment. <i>Neurology</i> , 2016, 87, 759-765.	1.1	264
148	Complex relationships. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e262.	6.0	0
149	Role of 18F-FDG-PET imaging in the diagnosis of autoimmune encephalitis – Authors' reply. <i>Lancet Neurology</i> , The, 2016, 15, 1010.	10.2	25
150	The clinical spectrum of Caspr2 antibody-associated disease. <i>Neurology</i> , 2016, 87, 521-528.	1.1	327
151	EphrinB2 prevents N-methyl-D-aspartate receptor antibody effects on memory and neuroplasticity. <i>Annals of Neurology</i> , 2016, 80, 388-400.	5.3	134
152	An interesting variety. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e201.	6.0	0
153	Alphabet soup. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e217.	6.0	0
154	Immunoproteomic studies on paediatric opsoclonus-myoclonus associated with neuroblastoma. <i>Journal of Neuroimmunology</i> , 2016, 297, 98-102.	2.3	3
155	Anti-NMDA receptor encephalitis, autoimmunity, and psychosis. <i>Schizophrenia Research</i> , 2016, 176, 36-40.	2.0	163
156	A clinical approach to diagnosis of autoimmune encephalitis. <i>Lancet Neurology</i> , The, 2016, 15, 391-404.	10.2	2,782
157	Clinical and Immunological Features of Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodies. <i>JAMA Neurology</i> , 2016, 73, 417.	9.0	152
158	Pitfalls in the detection of CV2 (CRMP5) antibodies. <i>Journal of Neuroimmunology</i> , 2016, 290, 80-83.	2.3	27
159	Orthostatic myoclonus associated with Caspr2 antibodies. <i>Neurology</i> , 2016, 86, 1353-1355.	1.1	41
160	Reply to: N-Methyl-D-Aspartate Receptor Autoantibodies in Psychiatric Illness. <i>Biological Psychiatry</i> , 2016, 79, e63.	1.3	1
161	Fat embolism showing restriction on diffusion sequence in brain magnetic resonance imaging. <i>Arquivos De Neuro-Psiquiatria</i> , 2016, 74, 597-598.	0.8	0
162	Name a brain protein, and an autoantibody shall be found!. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e159.	6.0	1

#	ARTICLE	IF	CITATIONS
163	Update on neurological paraneoplastic syndromes. <i>Current Opinion in Oncology</i> , 2015, 27, 489-495.	2.4	192
164	Investigations on CXCL13 in Anti-N-Methyl-D-Aspartate Receptor Encephalitis. <i>JAMA Neurology</i> , 2015, 72, 180.	9.0	142
165	Observations on the evolving fields of neuroimmunology and neuroinflammation. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e67.	6.0	2
166	The first anniversary issue. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e137.	6.0	0
167	Autoimmunity. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e181.	6.0	3
168	Encephalitis and AMPA receptor antibodies. <i>Neurology</i> , 2015, 84, 2403-2412.	1.1	311
169	Identifying targets for diagnosis, prognosis, and treatment. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e87.	6.0	1
170	Antibodies to dendritic neuronal surface antigens in opsoclonus myoclonus ataxia syndrome. <i>Journal of Neuroimmunology</i> , 2015, 286, 86-92.	2.3	33
171	Caspr2 autoantibodies target multiple epitopes. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e127.	6.0	32
172	Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies. <i>JAMA Neurology</i> , 2015, 72, 874.	9.0	169
173	Autoimmune Encephalitis in Postpartum Psychosis. <i>American Journal of Psychiatry</i> , 2015, 172, 901-908.	7.2	88
174	Status epilepticus of inflammatory etiology. <i>Neurology</i> , 2015, 85, 464-470.	1.1	64
175	Cellular plasticity induced by anti- α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies. <i>Annals of Neurology</i> , 2015, 77, 381-398.	5.3	122
176	Antibodies to Aquaporin 4, Myelin-Oligodendrocyte Glycoprotein, and the Glycine Receptor α 1 Subunit in Patients With Isolated Optic Neuritis. <i>JAMA Neurology</i> , 2015, 72, 187.	9.0	119
177	Autoimmune post-herpes simplex encephalitis of adults and teenagers. <i>Neurology</i> , 2015, 85, 1736-1743.	1.1	226
178	Clinico-pathological correlation in adenylate kinase 5 autoimmune limbic encephalitis. <i>Journal of Neuroimmunology</i> , 2015, 287, 31-35.	2.3	25
179	The growing spectrum of antibody-associated inflammatory brain diseases in children. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e92.	6.0	30
180	Anti-DPPX encephalitis. <i>Neurology</i> , 2015, 85, 890-897.	1.1	106

#	ARTICLE	IF	CITATIONS
181	Neuropathologic features of anti-dipeptidyl-peptidase-like protein-6 antibody encephalitis. <i>Neurology</i> , 2015, 84, 430-432.	1.1	20
182	Sleep disorder, chorea, and dementia associated with IgLON5 antibodies. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e136.	6.0	62
183	When a serum test overrides the clinical assessment. <i>Neurology</i> , 2015, 84, 1379-1381.	1.1	32
184	Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. <i>Multiple Sclerosis Journal</i> , 2015, 21, 866-874.	3.0	241
185	Autoimmune encephalopathies. <i>Annals of the New York Academy of Sciences</i> , 2015, 1338, 94-114.	3.8	322
186	Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. <i>Brain</i> , 2015, 138, 94-109.	7.6	391
187	Antibodies to Inhibitory Synaptic Proteins in Neurological Syndromes Associated with Glutamic Acid Decarboxylase Autoimmunity. <i>PLoS ONE</i> , 2015, 10, e0121364.	2.5	127
188	Comparison of Diagnostic Accuracy of Microscopy and Flow Cytometry in Evaluating N-Methyl-D-Aspartate Receptor Antibodies in Serum Using a Live Cell-Based Assay. <i>PLoS ONE</i> , 2015, 10, e0122037.	2.5	27
189	“The more we know” <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, .	6.0	0
190	Seizures as first symptom of anti-NMDA receptor encephalitis are more common in men. <i>Neurology</i> , 2014, 82, 550-551.	1.1	40
191	Neuronal Surface Antibody-Mediated Autoimmune Encephalitis. <i>Seminars in Neurology</i> , 2014, 34, 458-466.	1.4	57
192	Determination of Neuronal Antibodies in Suspected and Definite Creutzfeldt-Jakob Disease. <i>JAMA Neurology</i> , 2014, 71, 74.	9.0	59
193	Carbonic anhydrase-related protein <sc>VIII</sc> antibodies and paraneoplastic cerebellar degeneration. <i>Neuropathology and Applied Neurobiology</i> , 2014, 40, 650-653.	3.2	29
194	Antibodies to Delta/Notch-like Epidermal Growth Factor-Related Receptor in Patients With Anti-Tr, Paraneoplastic Cerebellar Degeneration, and Hodgkin Lymphoma. <i>JAMA Neurology</i> , 2014, 71, 1003.	9.0	49
195	Autoimmune encephalitis as differential diagnosis of infectious encephalitis. <i>Current Opinion in Neurology</i> , 2014, 27, 361-368.	3.6	148
196	Neuronal Antibodies in Creutzfeldt-Jakob Disease—Reply. <i>JAMA Neurology</i> , 2014, 71, 514.	9.0	5
197	Aggressive Course in Encephalitis With Opsoclonus, Ataxia, Chorea, and Seizures. <i>JAMA Neurology</i> , 2014, 71, 620.	9.0	63
198	A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. <i>Lancet Neurology</i> , The, 2014, 13, 575-586.	10.2	436

#	ARTICLE	IF	CITATIONS
199	Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. <i>Lancet Neurology</i> , The, 2014, 13, 276-286.	10.2	525
200	Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. <i>Annals of Neurology</i> , 2014, 75, 411-428.	5.3	405
201	Herpes simplex virus encephalitis is a trigger of brain autoimmunity. <i>Annals of Neurology</i> , 2014, 75, 317-323.	5.3	372
202	Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. <i>Lancet Neurology</i> , The, 2014, 13, 167-177.	10.2	758
203	A novel treatment-responsive encephalitis with frequent opsoclonus and teratoma. <i>Annals of Neurology</i> , 2014, 75, 435-441.	5.3	51
204	Reply. <i>Annals of Neurology</i> , 2014, 76, 464-465.	5.3	0
205	Autoimmune encephalitis update. <i>Neuro-Oncology</i> , 2014, 16, 771-778.	1.2	162
206	Cortactin autoantibodies in myasthenia gravis. <i>Autoimmunity Reviews</i> , 2014, 13, 1003-1007.	5.8	93
207	Antigenic and mechanistic characterization of anti-AMPA receptor encephalitis. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 180-189.	3.7	62
208	Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis. <i>Annals of Neurology</i> , 2014, 76, 108-119.	5.3	287
209	Sleep disorder associated with antibodies to IgLON5: parasomnia or agrypnia? Authors' reply. <i>Lancet Neurology</i> , The, 2014, 13, 864-865.	10.2	5
210	Serial brain 18FDG-PET in anti-AMPA receptor limbic encephalitis. <i>Journal of Neuroimmunology</i> , 2014, 271, 53-55.	2.3	35
211	Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. <i>Neurology</i> , 2014, 82, 879-886.	1.1	285
212	Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. <i>Blood</i> , 2014, 123, 3230-3238.	1.4	145
213	High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 822-832.	3.7	114
214	Optic Neuritis in the Setting of NMDA Receptor Encephalitis. <i>Journal of Neuro-Ophthalmology</i> , 2014, 34, 316-319.	0.8	6
215	Antibodies to N-methyl-D-aspartate and other synaptic receptors in choreoathetosis and relapsing symptoms post-herpes virus encephalitis. <i>Movement Disorders</i> , 2014, 29, 3-6.	3.9	31
216	Paraneoplastic Neurologic Syndromes. , 2014, , 597-607.e4.		0

#	ARTICLE	IF	CITATIONS
217	Frequency and Characteristics of Isolated Psychiatric Episodes in Anti-N-Methyl-D-Aspartate Receptor Encephalitis. JAMA Neurology, 2013, 70, 1133.	9.0	354
218	Diagnosis and Management of Paraneoplastic Neurologic Disorders. Current Treatment Options in Oncology, 2013, 14, 528-538.	3.0	49
219	Autoimmunity, seizures, and status epilepticus. Epilepsia, 2013, 54, 46-49.	5.1	62
220	Prevalence and treatment of anti-NMDA receptor encephalitis – Authors' reply. Lancet Neurology, The, 2013, 12, 425-426.	10.2	37
221	Encephalitis and antibodies to dipeptidyl-peptidase-like protein 6, a subunit of Kv4.2 potassium channels. Annals of Neurology, 2013, 73, 120-128.	5.3	305
222	Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurology, The, 2013, 12, 157-165.	10.2	2,382
223	Anti-NMDA Receptor Encephalitis and Other Autoimmune and Paraneoplastic Movement Disorders. , 2013, , 289-303.		0
224	Protein kinase C β antibodies and paraneoplastic cerebellar degeneration. Journal of Neuroimmunology, 2013, 256, 91-93.	2.3	23
225	Intrathecal injection of P/Q type voltage-gated calcium channel antibodies from paraneoplastic cerebellar degeneration cause ataxia in mice. Journal of Neuroimmunology, 2013, 261, 53-59.	2.3	42
226	Pediatric Anti-N-methyl-D-Aspartate Receptor Encephalitis – Clinical Analysis and Novel Findings in a Series of 20 Patients. Journal of Pediatrics, 2013, 162, 850-856.e2.	1.8	362
227	Persistent Intrathecal Antibody Synthesis 15 Years After Recovering From Anti-N-methyl-D-aspartate Receptor Encephalitis. JAMA Neurology, 2013, 70, 117.	9.0	66
228	Herpes simplex virus-1 encephalitis can trigger anti-NMDA receptor encephalitis: Case report. Neurology, 2013, 81, 1637-1639.	1.1	171
229	Glycine Receptor Autoimmune Spectrum With Stiff-Man Syndrome Phenotype. JAMA Neurology, 2013, 70, 44.	9.0	180
230	Patient With Homer-3 Antibodies and Cerebellitis. JAMA Neurology, 2013, 70, 506.	9.0	55
231	Encephalitis and GABA-B receptor antibodies. Neurology, 2013, 81, 1500-1506.	1.1	412
232	Paraneoplastic neuropathies. Current Opinion in Neurology, 2013, 26, 489-495.	3.6	48
233	Childhood Onset of Stiff-Man Syndrome. JAMA Neurology, 2013, 70, 1531.	9.0	65
234	Acquired Neuromyotonia Heraldng Recurrent Thymoma in Myasthenia Gravis. JAMA Neurology, 2013, 70, 1311-4.	9.0	29

#	ARTICLE	IF	CITATIONS
235	Late-onset anti-NMDA receptor encephalitis. <i>Neurology</i> , 2013, 81, 1058-1063.	1.1	169
236	Anti-N-methyl-D-aspartate receptor encephalitis presenting as paroxysmal exercise-induced foot weakness. <i>Movement Disorders</i> , 2013, 28, 820-822.	3.9	11
237	Antibody Repertoire in Paraneoplastic Cerebellar Degeneration and Small Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e60438.	2.5	70
238	An Optimized Immunohistochemistry Technique Improves NMO-IgG Detection: Study Comparison with Cell-Based Assays. <i>PLoS ONE</i> , 2013, 8, e79083.	2.5	39
239	Clinical Neuropathology practice guide 4-2013: post-herpes simplex encephalitis: N-methyl-D-aspartate receptor antibodies are part of the problem. , 2013, 32, 251-254.		42
240	Paraneoplastic Neurological Disorders in Leukemia and Lymphoma. , 2012, , 329-344.		0
241	Cognitive deficits following anti-NMDA receptor encephalitis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 195-198.	1.9	297
242	Central nervous system paraneoplastic disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 105, 853-864.	1.8	4
243	Clinical Reasoning: Agitation and psychosis in a patient after renal transplantation. <i>Neurology</i> , 2012, 79, e41-4.	1.1	17
244	Paraneoplastic neurological syndromes. <i>Current Opinion in Neurology</i> , 2012, 25, 795-801.	3.6	139
245	Serum IgG Antibodies Against the NR1 Subunit of the NMDA Receptor Not Detected in Schizophrenia. <i>American Journal of Psychiatry</i> , 2012, 169, 1120-1121.	7.2	93
246	Anti-N-methyl D-Aspartate Receptor Encephalitis Mimics Viral Encephalitis. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 202-204.	2.0	11
247	<i>Laboratoriums Medizin</i> , 2012, 35, ---.	0.6	3
248	N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. <i>Annals of Neurology</i> , 2012, 72, 902-911.	5.3	343
249	The Frequency of Autoimmune N-Methyl-D-Aspartate Receptor Encephalitis Surpasses That of Individual Viral Etiologies in Young Individuals Enrolled in the California Encephalitis Project. <i>Clinical Infectious Diseases</i> , 2012, 54, 899-904.	5.8	619
250	Anti-NMDA Receptor Encephalitis Antibody Binding Is Dependent on Amino Acid Identity of a Small Region within the GluN1 Amino Terminal Domain. <i>Journal of Neuroscience</i> , 2012, 32, 11082-11094.	3.6	247
251	Extreme delta brush. <i>Neurology</i> , 2012, 79, 1094-1100.	1.1	614
252	Paraneoplastic syndromes and autoimmune encephalitis. <i>Neurology: Clinical Practice</i> , 2012, 2, 215-223.	1.6	70

#	ARTICLE	IF	CITATIONS
253	Neuronal autoantigensâ€™ pathogenesis, associated disorders and antibody testing. Nature Reviews Neurology, 2012, 8, 380-390.	10.1	424
254	Paraneoplastic neurologic disorders: a brief overview. Memo - Magazine of European Medical Oncology, 2012, 5, 197-200.	0.5	8
255	Autoimmune Encephalitis in Children. Journal of Child Neurology, 2012, 27, 1460-1469.	1.4	178
256	Autoimmune Encephalitis. European Neurological Review, 2012, 8, 31.	0.5	56
257	Clinical neuropathology practice guide 5-2012: Updated guideline for the diagnosis of antineuronal antibodies. , 2012, 31, 337-341.		34
258	Rituximab as potential therapy for paraneoplastic cerebellar degeneration in pediatric Hodgkin disease. Pediatric Blood and Cancer, 2012, 58, 986-987.	1.5	12
259	Fluorodeoxyglucose positron emission tomography in anti-N-methyl-D-aspartate receptor encephalitis: distinct pattern of disease. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 681-686.	1.9	166
260	CNS autoimmunity: new findings and pending issues. Lancet Neurology, The, 2012, 11, 17-19.	10.2	22
261	Reversible paraneoplastic encephalitis in three patients with ovarian neoplasms. Acta Obstetrica Et Gynecologica Scandinavica, 2012, 91, 630-634.	2.8	29
262	Analysis of antibodies to surface epitopes of contactin-2 in multiple sclerosis. Journal of Neuroimmunology, 2012, 244, 103-106.	2.3	21
263	Ung jente med psykose, kognitiv svikt og kramper. Tidsskrift for Den Norske Lægeforening, 2012, 132, 2073-2076.	0.2	13
264	Cancer and the Nervous System. , 2012, , 1200-1210.		1
265	The Emerging Link Between Autoimmune Disorders and Neuropsychiatric Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 90-97.	1.8	102
266	Movement disorders in paraneoplastic and autoimmune disease. Current Opinion in Neurology, 2011, 24, 346-353.	3.6	94
267	Pseudo-Piano Playing Motions and Nocturnal Hypoventilation in Anti-NMDA Receptor Encephalitis: Response to Prompt Tumor Removal and Immunotherapy. Internal Medicine, 2011, 50, 627-630.	0.7	31
268	Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force. European Journal of Neurology, 2011, 18, 19.	3.3	489
269	Paraneoplastic disorders of eye movements. Annals of the New York Academy of Sciences, 2011, 1233, 279-284.	3.8	28
270	Anti-NMDA-receptor encephalitis: A severe, multistage, treatable disorder presenting with psychosis. Journal of Neuroimmunology, 2011, 231, 86-91.	2.3	209

#	ARTICLE	IF	CITATIONS
271	Thymoma-associated paraneoplastic encephalitis (TAPE): Diagnosis and treatment of a potentially fatal condition. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2011, 141, e17-e20.	0.8	17
272	Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. <i>Lancet Neurology</i> , The, 2011, 10, 63-74.	10.2	2,039
273	Anti-NMDA-receptor encephalitis in a 3 year old patient with chromosome 6p21.32 microdeletion including the HLA cluster. <i>European Journal of Paediatric Neurology</i> , 2011, 15, 163-166.	1.6	27
274	Case 34-2011. <i>New England Journal of Medicine</i> , 2011, 365, 1825-1833.	27.0	14
275	Perfusion ¹²³ IMPâ€‘SPECT shows reversible abnormalities in GABA _B receptor antibody associated encephalitis with normal MRI. <i>Brain and Behavior</i> , 2011, 1, 70-72.	2.2	15
276	Afferent facilitation of corticomotor responses is increased by IgGs of patients with NMDA-receptor antibodies. <i>Journal of Neurology</i> , 2011, 258, 27-33.	3.6	36
277	Anti-N-methyl-d-aspartate receptor encephalitis associated with carcinosarcoma with neuroendocrine differentiation of the uterus. <i>Journal of Neurology</i> , 2011, 258, 1351-1353.	3.6	24
278	Paraneoplastic anti-NMDAR encephalitis: long term follow-up reveals persistent serum antibodies. <i>Journal of Neurology</i> , 2011, 258, 1568-1570.	3.6	36
279	Antiâ€‘NMDA-Receptor Encephalitis and Other Synaptic Autoimmune Disorders. <i>Current Treatment Options in Neurology</i> , 2011, 13, 324-332.	1.8	69
280	Paraneoplastic Neurologic Disorders in Children. <i>Current Neurology and Neuroscience Reports</i> , 2011, 11, 187-194.	4.2	24
281	Isolated hemidystonia associated with NMDA receptor antibodies. <i>Movement Disorders</i> , 2011, 26, 351-352.	3.9	46
282	A case of slow orthostatic tremor, responsive to intravenous immunoglobulin. <i>Movement Disorders</i> , 2011, 26, 1563-1565.	3.9	13
283	Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. <i>Annals of Neurology</i> , 2011, 69, 303-311.	5.3	371
284	Scleromyxedema and dermatomyositis syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib. <i>American Journal of Hematology</i> , 2011, 86, 893-896.	4.1	29
285	Antiâ€‘N-methylâ€‘D-aspartate receptor encephalitis: A newly recognized inflammatory brain disease in children. <i>Arthritis and Rheumatism</i> , 2011, 63, 2516-2522.	6.7	70
286	Tonic seizures: A diagnostic clue of anti-LGI1 encephalitis?. <i>Neurology</i> , 2011, 76, 1355-1357.	1.1	135
287	Encephalitis and antibodies to synaptic and neuronal cell surface proteins. <i>Neurology</i> , 2011, 77, 179-189.	1.1	379
288	Neue serologische Marker zur Differentialdiagnose der Autoimmun-Enzephalitis/New serological markers for the differential diagnosis of autoimmune limbic encephalitis. <i>Laboratoriums Medizin</i> , 2011, 35, 329-342.	0.6	4

#	ARTICLE	IF	CITATIONS
289	Paraneoplastic syndromes causing movement disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2011, 100, 315-321.	1.8	6
290	Prolonged Follow-up and CSF Antibody Titers in a Patient With Anti-NMDA Receptor Encephalitis. Neurology, 2011, 76, S64-6.	1.1	50
291	Anti-NMDA Receptor Encephalitis in Psychiatry. Current Psychiatry Reviews, 2011, 7, 189-193.	0.9	147
292	Update on anti-N-methyl-D-aspartate receptor encephalitis in children and adolescents. Current Opinion in Pediatrics, 2010, 22, 739-744.	2.0	95
293	Laparoscopic epilepsy surgery. Intensive Care Medicine, 2010, 36, 367-368.	8.2	2
294	Antibodies and neuronal autoimmune disorders of the CNS. Journal of Neurology, 2010, 257, 509-517.	3.6	338
295	Reversible brain atrophy in anti-NMDA receptor encephalitis: a long-term observational study. Journal of Neurology, 2010, 257, 1686-1691.	3.6	106
296	Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurology, The, 2010, 9, 67-76.	10.2	805
297	Complement-mediated cytotoxicity of antibodies to the GABAB receptor â€“ Authors' reply. Lancet Neurology, The, 2010, 9, 343-344.	10.2	2
298	Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurology, The, 2010, 9, 776-785.	10.2	947
299	Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies. European Journal of Neuroscience, 2010, 32, 298-309.	2.6	104
300	Paraneoplastic Disorders. Blue Books of Neurology, 2010, , 411-430.	0.1	0
301	Cellular and Synaptic Mechanisms of Anti-NMDA Receptor Encephalitis. Journal of Neuroscience, 2010, 30, 5866-5875.	3.6	959
302	Anti-NMDA receptor encephalitis causing prolonged nonconvulsive status epilepticus. Neurology, 2010, 75, 1480-1482.	1.1	125
303	Update on Paraneoplastic Neurologic Disorders. Oncologist, 2010, 15, 603-617.	3.7	23
304	Anti-N-methyl-D-aspartate Receptor Encephalitis During Pregnancy. Archives of Neurology, 2010, 67, 884-7.	4.5	75
305	Update on Paraneoplastic and Autoimmune Disorders of the Central Nervous System. Seminars in Neurology, 2010, 30, 320-331.	1.4	39
306	Neurologic Complications of Cancer. Seminars in Neurology, 2010, 30, 215-216.	1.4	0

#	ARTICLE	IF	CITATIONS
307	Psychiatric Manifestations of Paraneoplastic Disorders. American Journal of Psychiatry, 2010, 167, 1039-1050.	7.2	120
308	In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction. Orphanet Journal of Rare Diseases, 2010, 5, 31.	2.7	102
309	Glazed (Vision) and Confused. Survey of Ophthalmology, 2010, 55, 169-173.	4.0	14
310	Update on paraneoplastic neurologic disorders. Community Oncology, 2010, 7, 219-224.	0.2	18
311	Anti-N-methyl-D-aspartate Receptor Encephalitis. Archives of Neurology, 2010, 67, 250-1.	4.5	24
312	Paraneoplastic disorders of the memory and cognition. , 2009, , 377-394.		2
313	Acute psychiatric illness in a young woman: an unusual form of encephalitis. Medical Journal of Australia, 2009, 191, 284-286.	1.7	32
314	Recognizing Paraneoplastic Limbic Encephalitis. Journal of Clinical Oncology, 2009, 27, e230-e231.	1.6	8
315	A multimodality approach to reversible paraneoplastic encephalitis associated with ovarian teratomas. Acta Oncologica, 2009, 48, 1079-1082.	1.8	1
316	Diagnostic Value of N-methyl-D-aspartate Receptor Antibodies in Women With New-Onset Epilepsy. Archives of Neurology, 2009, 66, 458-64.	4.5	158
317	AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Annals of Neurology, 2009, 65, 424-434.	5.3	712
318	Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Annals of Neurology, 2009, 66, 11-18.	5.3	969
319	Reduced N-acetylaspartate in the basal ganglia of a patient with anti-NMDA receptor encephalitis. Movement Disorders, 2009, 24, 784-786.	3.9	19
320	Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathologica, 2009, 118, 737-743.	7.7	296
321	Status epilepticus due to paraneoplastic and nonparaneoplastic encephalitides. Epilepsia, 2009, 50, 58-60.	5.1	53
322	Reversible limbic encephalitis with antibodies against the membranes of neurones of the hippocampus. BMJ Case Reports, 2009, 2009, bcr0720080509-bcr0720080509.	0.5	4
323	Paraneoplastic syndromes of the CNS. Lancet Neurology, The, 2008, 7, 327-340.	10.2	772
324	Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurology, The, 2008, 7, 1091-1098.	10.2	2,696

#	ARTICLE	IF	CITATIONS
325	Functional analysis of CD8+ T cell responses to the onconeural self protein cdr2 in patients with paraneoplastic cerebellar degeneration. Journal of Neuroimmunology, 2008, 193, 173-182.	2.3	17
326	ZIC antibodies in paraneoplastic cerebellar degeneration and small cell lung cancer. Journal of Neuroimmunology, 2008, 201-202, 163-165.	2.3	46
327	Paraneoplastic Syndromes of the Nervous System. , 2008, , 237-255.		1
328	Paraneoplastic disorders of the memory and cognition: clinical aspects and therapeutic approaches. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 873-876.	1.8	1
329	TREATMENT-RESPONSIVE SUBACUTE LIMBIC ENCEPHALITIS AND NMDA RECEPTOR ANTIBODIES IN A MAN. Neurology, 2008, 70, 728-729.	1.1	55
330	Inverse Ocular Bobbing in a Patient With Encephalitis Associated With Antibodies to the N-methyl-D-aspartate Receptor. Archives of Neurology, 2008, 65, 1251.	4.5	15
331	Paraneoplastic neurological syndromes: diagnosis and treatment. Current Opinion in Internal Medicine, 2008, 7, 82-87.	1.5	36
332	Neuro-Ophthalmologic Manifestations of Paraneoplastic Syndromes. Journal of Neuro-Ophthalmology, 2008, 28, 58-68.	0.8	83
333	Paraneoplastic Neurologic Syndromes. , 2008, , 767-778.		1
334	Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome. Nature Clinical Practice Neurology, 2007, 3, 405-410.	2.5	61
335	Case 4-2007. New England Journal of Medicine, 2007, 356, 612-620.	27.0	32
336	THYMOMA, MYASTHENIA GRAVIS, ENCEPHALITIS, AND A NOVEL ANTICYTOPLASMIC NEURONAL ANTIBODY. Neurology, 2007, 69, 1302-1303.	1.1	3
337	Limbic Encephalitis and Variants: Classification, Diagnosis and Treatment. Neurologist, 2007, 13, 261-271.	0.7	339
338	Paraneoplastic disorders of the nervous system. European Journal of Cancer, Supplement, 2007, 5, 53-67.	2.2	1
339	Paraneoplastic limbic encephalitis associated with small-cell lung cancer. Community Oncology, 2007, 4, 491-494.	0.2	6
340	A patient with encephalitis associated with NMDA receptor antibodies. Nature Clinical Practice Neurology, 2007, 3, 291-296.	2.5	245
341	Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Annals of Neurology, 2007, 61, 25-36.	5.3	2,166
342	Severe hypokinesia caused by paraneoplastic anti-Ma2 encephalitis associated with bilateral intratubular germ-cell neoplasm of the testes. Movement Disorders, 2007, 22, 728-731.	3.9	37

#	ARTICLE	IF	CITATIONS
343	Adenylate kinase 5 autoimmunity in treatment refractory limbic encephalitis. Journal of Neuroimmunology, 2007, 186, 177-180.	2.3	51
344	Paraneoplastic Neurological Disorders. , 2007, , 163-169.		0
345	Paraneoplastic Neurologic Syndromes. , 2007, , 517-533.		0
346	Clinical and Immunological Diversity of Limbic Encephalitis: A Model for Paraneoplastic Neurologic Disorders. Hematology/Oncology Clinics of North America, 2006, 20, 1319-1335.	2.2	48
347	Paraneoplastic cerebellar degeneration: Yo-expressing tumor revealed after a 5-year follow-up with FDG-PET. Journal of the Neurological Sciences, 2006, 250, 153-155.	0.6	35
348	Herpes simplex encephalitis in a patient with cancer. Journal of Neuro-Oncology, 2006, 78, 211-211.	2.9	2
349	EFA6A-like antibodies in paraneoplastic encephalitis associated with immature ovarian teratoma: a case report. Journal of Neuro-Oncology, 2006, 81, 71-74.	2.9	43
350	Current therapies for neuromuscular manifestations of paraneoplastic syndromes. Current Neurology and Neuroscience Reports, 2006, 6, 77-84.	4.2	10
351	Anti-Ma2-associated encephalitis with normal FDG-PET: a case of pseudo-Whipple's disease. Nature Clinical Practice Neurology, 2006, 2, 566-572.	2.5	41
352	Remote Effects of Cancer: Treatment of Paraneoplastic Neurologic Syndromes. , 2006, , 274-280.		0
353	PARANEOPLASTIC DISORDERS OF THE NERVOUS SYSTEM. CONTINUUM Lifelong Learning in Neurology, 2005, 11, 69-92.	0.8	0
354	Paraneoplastic syndromes of the peripheral nerves. Current Opinion in Neurology, 2005, 18, 598-603.	3.6	88
355	Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Annals of Neurology, 2005, 58, 594-604.	5.3	516
356	Paraneoplastic recurrent multifocal encephalitis presenting with epilepsy partialis continua. Journal of Neuro-Oncology, 2005, 72, 63-66.	2.9	32
357	Metastases to the peripheral nervous system. Journal of Neuro-Oncology, 2005, 75, 101-110.	2.9	39
358	Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain, 2005, 128, 1764-1777.	7.6	434
359	Clinical analysis of anti-Ma2-associated encephalitis. Brain, 2004, 127, 1831-1844.	7.6	681
360	Unusual neuro-ophthalmologic findings in a patient with anti-Yo-associated cerebellar degeneration. Journal of the Neurological Sciences, 2004, 225, 153-155.	0.6	5

#	ARTICLE	IF	CITATIONS
361	Neuro-ophthalmology and paraneoplastic syndromes. Current Opinion in Neurology, 2004, 17, 3-8.	3.6	63
362	Anti-GAD Antibody Positive Stiff-Limb Syndrome in Multiple Myeloma. Journal of Neuro-Oncology, 2003, 65, 173-175.	2.9	33
363	Current therapies for paraneoplastic neurologic syndromes. Current Treatment Options in Neurology, 2003, 5, 69-77.	1.8	29
364	The MAZ protein is an autoantigen of Hodgkin's disease and paraneoplastic cerebellar dysfunction. Annals of Neurology, 2003, 53, 123-127.	5.3	19
365	Autoantigen diversity in the opsoclonus-myoclonus syndrome. Annals of Neurology, 2003, 53, 347-353.	5.3	138
366	Paraneoplastic neurologic syndromes. Neurologic Clinics, 2003, 21, 221-247.	1.8	42
367	Paraneoplastic Neurologic Syndromes: Approaches to Diagnosis and Treatment. Seminars in Neurology, 2003, 23, 215-224.	1.4	39
368	Paraneoplastic Sensory Neuronopathy and Spontaneous Regression of Small Cell Lung Cancer. Canadian Journal of Neurological Sciences, 2003, 30, 269-271.	0.5	54
369	Paraneoplastic Syndromes of the Nervous System. , 2003, , 159-169.		1
370	Paraneoplastic Syndromes, Central. , 2003, , 784-787.		0
371	Paraneoplastic Syndromes, Immunology. , 2003, , 787-790.		0
372	Paraneoplastic Syndromes. , 2003, , 1146-1156.		0
373	Anti-Hu antibodies in Merkel cell carcinoma. Annals of Neurology, 2002, 52, 111-115.	5.3	24
374	THE CLINICAL SPECTRM AND PATHOGENESIS OF PARANEOPLASTIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM. Hematology/Oncology Clinics of North America, 2001, 15, 1109-1128.	2.2	4
375	The Photoreceptor Cell-Specific Nuclear Receptor is an Autoantigen of Paraneoplastic Retinopathy. Journal of Neuro-Ophthalmology, 2001, 21, 168-172.	0.8	33
376	Anti-Ri-associated paraneoplastic opsoclonus-ataxia syndrome in a man with transitional cell carcinoma. Cancer, 2001, 91, 1423-1428.	4.1	42
377	Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Annals of Neurology, 2001, 50, 339-348.	5.3	256
378	Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Annals of Neurology, 2001, 50, 339-348.	5.3	2

#	ARTICLE	IF	CITATIONS
379	Paraneoplastic syndromes of the spinal cord, nerve, and muscle. <i>Muscle and Nerve</i> , 2000, 23, 1800-1818.	2.2	88
380	Hu Immunolabeling as a Marker of Neural and Neuroendocrine Differentiation in Normal and Neoplastic Human Tissues: Assessment Using a Recombinant Anti-Hu Fab Fragment. <i>International Journal of Surgical Pathology</i> , 2000, 8, 109-117.	0.8	28
381	Antineuronal Antibodies in Patients With Neuroblastoma and Paraneoplastic Opsoclonus-Myoclonus. <i>The American Journal of Pediatric Hematology/Oncology</i> , 2000, 22, 315-320.	1.3	129
382	Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. <i>Brain</i> , 1999, 122, 27-39.	7.6	219
383	A Serologic Marker of Paraneoplastic Limbic and Brain-Stem Encephalitis in Patients with Testicular Cancer. <i>New England Journal of Medicine</i> , 1999, 340, 1788-1795.	27.0	356
384	DEF-3(g16/NY-LU-12), an RNA binding protein from the 3p21.3 homozygous deletion region in SCLC. <i>Oncogene</i> , 1999, 18, 2589-2597.	5.9	40
385	Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. <i>Annals of Neurology</i> , 1999, 45, 162-167.	5.3	155
386	Association of anti-Yo (type I) antibody with paraneoplastic cerebellar degeneration in the setting of transitional cell carcinoma of the bladder: Detection of Yo antigen in tumor tissue and fall in antibody titers following tumor removal. <i>Annals of Neurology</i> , 1999, 45, 805-809.	5.3	37
387	Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders. <i>Annals of Neurology</i> , 1999, 46, 774-777.	5.3	103
388	P/Q-type voltage-gated calcium channel antibodies in paraneoplastic disorders of the central nervous system. , 1999, 22, 119-122.		56
389	Paraneoplastic Neurologic Syndromes: Pathogenesis and Physiopathology. <i>Brain Pathology</i> , 1999, 9, 275-284.	4.1	145
390	Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. , 1999, 45, 162.		1
391	Neuronal molecular mimicry in immune-mediated neurologic disease. <i>Annals of Neurology</i> , 1998, 44, 87-98.	5.3	70
392	Small-cell carcinoma of the lung presenting with paraneoplastic peripheral nerve microvasculitis and optic neuropathy. , 1998, 21, 1358-1359.		27
393	Localization of the neuronal antigen recognized by anti-Tr antibodies from patients with paraneoplastic cerebellar degeneration and Hodgkin's disease in the rat nervous system. <i>Acta Neuropathologica</i> , 1998, 96, 1-7.	7.7	58
394	T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. <i>Neurology</i> , 1998, 51, 1146-1150.	1.1	157
395	Anti-Hu Immunolabeling as an Index of Neuronal Differentiation in Human Brain Tumors. <i>American Journal of Surgical Pathology</i> , 1998, 22, 195-200.	3.7	36
396	Normalization of the Tumor Marker CA-125 after Oophorectomy in a Patient with Paraneoplastic Cerebellar Degeneration without Detectable Cancer. <i>Gynecologic Oncology</i> , 1997, 65, 173-176.	1.4	16

#	ARTICLE	IF	CITATIONS
397	Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. <i>Journal of Neuroimmunology</i> , 1997, 74, 55-61.	2.3	204
398	Paraneoplastic anti-Hu serum: studies on human tumor cell lines. <i>Journal of Neuroimmunology</i> , 1997, 79, 202-210.	2.3	41
399	A Post-Transcriptional Regulatory Mechanism Restricts Expression of the Paraneoplastic Cerebellar Degeneration Antigen cdr2 to Immune Privileged Tissues. <i>Journal of Neuroscience</i> , 1997, 17, 1406-1415.	3.6	110
400	The use of paraffin-embedded tissue for detection of antineuronal antibodies. <i>Acta Neuropathologica</i> , 1997, 94, 300-301.	7.7	0
401	Paraneoplastic opsomyoclonus, cerebellar ataxia and encephalopathy associated with anti-Purkinje cell antibodies. <i>Journal of Neurology</i> , 1997, 244, 333-335.	3.6	13
402	Paraneoplastic syndromes. <i>Current Opinion in Immunology</i> , 1997, 9, 723-729.	5.5	40
403	Motor neuron syndromes in cancer patients. <i>Annals of Neurology</i> , 1997, 41, 722-730.	5.3	175
404	The E. Graeme Robertson Lecture. <i>Journal of Clinical Neuroscience</i> , 1996, 3, 8-15.	1.5	3
405	Neurological paraneoplastic syndromes. <i>Seminars in Immunopathology</i> , 1996, 18, 85-95.	4.0	13
406	Neurological paraneoplastic syndromes. , 1996, , 203-213.		0
407	[16] Characterization of neuronal antigens and antineuronal antibodies. <i>Methods in Neurosciences</i> , 1995, , 261-271.	0.5	5
408	Hu antigens: Reactivity with hu antibodies, tumor expression, and major immunogenic sites. <i>Annals of Neurology</i> , 1995, 38, 102-110.	5.3	162
409	Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. <i>Cancer</i> , 1995, 75, 99-109.	4.1	159
410	Clinical enigmas of paraneoplastic neurologic disorders. <i>Clinical Neurology and Neurosurgery</i> , 1995, 97, 61-70.	1.4	19
411	Transfer and Expression of Antioncogenes and Paraneoplastic Genes in Normal and Neoplastic Cells in Vitro and in Vivo. , 1995, , 275-VIII.		0
412	Immunological and pathological study of anti-Ri-associated encephalopathy. <i>Annals of Neurology</i> , 1994, 36, 896-902.	5.3	113
413	Cloning and characterization of a lambert-eaton myasthenic syndrome antigen. <i>Annals of Neurology</i> , 1993, 33, 113-120.	5.3	68
414	The neuronal nuclear antigen recognized by the human anti-Ri autoantibody is expressed in central but not peripheral nervous system neurons. <i>Neuroscience Letters</i> , 1993, 150, 212-214.	2.1	43

#	ARTICLE	IF	CITATIONS
415	Paraneoplastic Syndromes and Progressive Motor Dysfunction. Seminars in Neurology, 1993, 13, 291-298.	1.4	7
416	Anti-Hu-Associated Paraneoplastic Encephalomyelitis/Sensory Neuronopathy A Clinical Study of 71 Patients. Medicine (United States), 1992, 71, 59-72.	1.0	732
417	p53 gene mutations in primary lung tumors are conserved in brain metastases. Journal of Neuro-Oncology, 1992, 14, 93-100.	2.9	17
418	HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elav and sex-lethal. Cell, 1991, 67, 325-333.	28.9	572
419	Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer?A quantitative western blot analysis. Annals of Neurology, 1990, 27, 544-552.	5.3	375
420	Selective Expression of Purkinje-Cell Antigens in Tumor Tissue from Patients with Paraneoplastic Cerebellar Degeneration. New England Journal of Medicine, 1990, 322, 1844-1851.	27.0	287
421	Paraneoplastic movement disorders. , 0, , 39-51.		0